目的 探讨PLK1和CDC20在乳腺癌组织中的表达情况,并分析两者表达与临床病理特征及预后的关系.方法 基于cBioPortal数据库和癌症基因图谱(TCGA)数据库中1092例乳腺癌患者的临床资料和mRNA芯片数据,分析PLK1和CDC20的表达情况.采用Kaplan-Meier法和Cox风险比例回归模型分析PLK1和CDC20的表达水平与乳腺癌患者预后的关系.采用卡方检验分析PLK1和CDC20的表达与患者年龄、性别及ER、PR、HER-2基因表达之间的关系.结果 PLK1与CDC20在乳腺癌中的表达呈正相关(r=0.88,P＜0.001),并且两者表达均与乳腺癌患者的无病生存期(DFS)有关(P均＜0.05),PLK1与CDC20同时高表达与同时低表达的患者相比,DFS显著缩短(P=0.007).同时PLK1和CDC20在ER、PR阴性患者肿瘤组织中的表达水平均显著高于ER、PR阳性患者(P均＜0.001).结论 PLK1和CDC20在乳腺癌中可能起到促进肿瘤转移的作用,可以作为预测肿瘤转移的潜在生物标志物及个体化治疗靶点.%Objective To explore the expression of polo-like kinase 1 (PLK1) and cell-division cycle protein 20 (CDC20) in breast cancer as well as the relationship of their expression with clinicopathological features and prognosis.Methods The expression datasets of PLK1 and CDC20 from cBioPortal database were collected to analyze the co-expressions of these two genes.The clinical data and mRNA microarray data of 1092 patients with breast cancer obtained from the Cancer Genome Atlas(TCGA) database were collected and analyzed for expression of PLK1 and CDC20.The Kaplan-Meier method and Cox proportional-hazards regression model was used to analyze the relationship between the expressions of PLK1 or CDC20 and the survival of patients with breast cancer.The relationships between PLK1 or CDC20 and age,gender and ER,PR or HER-2 genes expression levels were further analyzed byx2 test.Results The expression levels of PLK1 and CDC20 in breast cancer were significantly correlated (r=0.88,P＜0.001).Also,the expressions of PLK1 and CDC20 significantly was related to the disease free survival (DFS) of patients with breast cancer(P＜0.05).Patients with high expression of PLK1 and CDC20 had short DFS compared with patients with low expression of both (P=0.007).At the same time,the expression levels of PLK1 and CDC20 in ER negative and PR negative patients were significantly higher than those in ER positive and PR positive patients (P＜0.001).Conclusion PLK1 and CDC20 may play a role in promoting tumorigenesis in breast cancer,and may serve as potential tumor diagnostic markers and individual therapeutic targets.
展开▼
